These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31204269)

  • 1. Perioperative Buprenorphine.
    Wolfe RC
    J Perianesth Nurs; 2019 Aug; 34(4):867-870. PubMed ID: 31204269
    [No Abstract]   [Full Text] [Related]  

  • 2. Peripartum Anesthetic Management of the Opioid-tolerant or Buprenorphine/Suboxone-dependent Patient.
    Pan A; Zakowski M
    Clin Obstet Gynecol; 2017 Jun; 60(2):447-458. PubMed ID: 28426507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Kratom Withdrawal and Addiction With Buprenorphine.
    Khazaeli A; Jerry JM; Vazirian M
    J Addict Med; 2018; 12(6):493-495. PubMed ID: 30383616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 5. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period.
    Lembke A; Ottestad E; Schmiesing C
    Pain Med; 2019 Mar; 20(3):425-428. PubMed ID: 29452378
    [No Abstract]   [Full Text] [Related]  

  • 6. Rapid Induction Therapy for Opioid-Use Disorder Using Buprenorphine Transdermal Patch: A Case Series.
    Saal D; Lee F
    Perm J; 2020; 24():. PubMed ID: 32240088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.
    Klaire S; Zivanovic R; Barbic SP; Sandhu R; Mathew N; Azar P
    Am J Addict; 2019 Jul; 28(4):262-265. PubMed ID: 30901127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):35-37. PubMed ID: 29485976
    [No Abstract]   [Full Text] [Related]  

  • 10. Perioperative Buprenorphine Management: A Multidisciplinary Approach.
    Hickey T; Abelleira A; Acampora G; Becker WC; Falker CG; Nazario M; Weimer MB
    Med Clin North Am; 2022 Jan; 106(1):169-185. PubMed ID: 34823729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative Management and Analgesia for Patients Taking Buprenorphine and Other Forms of Medication-Assisted Treatment for Substance Abuse Disorders.
    Scholzen E; Zeng AM; Schroeder KM
    Adv Anesth; 2019 Dec; 37():65-86. PubMed ID: 31677660
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients.
    Baykara S; Alban K
    Psychiatry Res; 2019 Feb; 272():450-453. PubMed ID: 30611963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.
    Vocci FJ; Schwartz RP; Wilson ME; Gordon MS; Kinlock TW; Fitzgerald TT; O'Grady KE; Jaffe JH
    Drug Alcohol Depend; 2015 Nov; 156():133-138. PubMed ID: 26409751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Kratom Dependence With Buprenorphine-Naloxone Maintenance.
    Buresh M
    J Addict Med; 2018; 12(6):481-483. PubMed ID: 29944481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuation of Buprenorphine to Facilitate Postoperative Pain Management for Patients on Buprenorphine Opioid Agonist Therapy.
    Mehta D; Thomas V; Johnson J; Scott B; Cortina S; Berger L
    Pain Physician; 2020 Mar; 23(2):E163-E174. PubMed ID: 32214293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Shelby Clinic Medication-Assisted Treatment for Opioid Addiction.
    Penn CL
    J Ark Med Soc; 2016 Aug; 113(2):30-32. PubMed ID: 30047628
    [No Abstract]   [Full Text] [Related]  

  • 17. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
    DiPaula BA; Menachery E
    J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women.
    Cleary EM; Byron RK; Hinely KA; Talley AW; Costantine MM; Rood KM
    Obstet Gynecol; 2020 Nov; 136(5):902-903. PubMed ID: 33030872
    [No Abstract]   [Full Text] [Related]  

  • 19. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
    Azar P; Nikoo M; Miles I
    Am J Addict; 2018 Dec; 27(8):601-604. PubMed ID: 30387894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.
    Hoffman K; Peyton ML; Sumner M
    J Addict Med; 2017; 11(3):217-223. PubMed ID: 28353467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.